<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581630</url>
  </required_header>
  <id_info>
    <org_study_id>3-2017-0097</org_study_id>
    <nct_id>NCT03581630</nct_id>
  </id_info>
  <brief_title>Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients</brief_title>
  <official_title>Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment on Body Weight and Metabolic Risk Factors in Obese Breast Cancer Patients After Breast Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gangnam Severance Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity among breast cancer survivors is known to be associated with recurrence and other
      co-morbidities. However, there have been no studies on weight reduction program combining
      diet and anti-obesity drug for obese breast cancer survivors. The purpose of this randomized
      clinical trial is to examine the effects of Mediterranean Diet and naltrexone/bupropion
      treatment on inflammation and metabolic risk factors in overweight or obese breast cancer
      patients after breast cancer treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2017</start_date>
  <completion_date type="Actual">July 22, 2018</completion_date>
  <primary_completion_date type="Actual">July 22, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>body weight (kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fat mass</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>fat mass (kg) measured by bioelectrical impedance analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in muscle mass</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>muscle mass (kg) measured by bioelectrical impedance analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in fasting glucose</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>fasting glucose (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in insulin</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>insulin (mcIU/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in triglyceride</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>triglyceride (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in high-density lipoprotein cholesterol (HDL-cholesterol)</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>HDL-cholesterol (mg/dL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in leukocyte count</measure>
    <time_frame>baseline, 8 weeks</time_frame>
    <description>leukocyte count (/μL)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer subjects-Mediterranean Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects-naltrexone/bupropion+Mediterranean Diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone/bupropion</intervention_name>
    <description>Naltrexone hydrochloride (HCl) 8 mg/Bupropion hydrochloride (HCl) 90 mg extended release (ER) combination tablets, orally, one tablet, in the morning, daily, for 1 week, followed by Naltrexone HCl 8 mg/Bupropion HCl 90 mg ER combination tablets, orally, one tablet in the morning and one in the evening, daily, for 7 weeks.</description>
    <arm_group_label>Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet</arm_group_label>
    <arm_group_label>Healthy subjects-naltrexone/bupropion+Mediterranean Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mediterranean Diet</intervention_name>
    <description>Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.</description>
    <arm_group_label>Breast cancer subjects-Mediterranean Diet</arm_group_label>
    <arm_group_label>Breast cancer subjects-naltrexone/bupropion+Mediterranean Diet</arm_group_label>
    <arm_group_label>Healthy subjects-naltrexone/bupropion+Mediterranean Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female, 20 to 65 years of age

          -  Diagnosed with breast cancer stage Ⅰ-Ⅲ, and have completed cancer treatment including
             breast surgery and/or adjuvant chemotherapy, radiotherapy, hormonal therapy

          -  BMI ≥25 kg/m2, or BMI ≥23 kg/m2 with one or more of the metabolic risk factors (waist
             circumference ≥80 cm, fasting glucose ≥100 mg/dL, BP ≥130/85 mmHg, HDL-cholesterol &lt;50
             mg/dL or controlled diabetes, hypertension, dyslipidemia with medications)

          -  If woman of child bearing potential, agree to use effective contraception throughout
             the study period and 30 days after discontinuation of study drug

          -  Able to speak and read Korean

          -  Able to comply with all required study procedures and schedule

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Participants with cancer recurrence or metastasis

          -  Participants with uncontrolled hypertension (systolic blood pressure (SBP) &gt;180 mmHg,
             or diastolic blood pressure (DBP) &gt;120 mmHg)

          -  Participants with hepatic disease (aspartate aminotransferase (AST)/alanine
             aminotransferase (ALT) &gt;3 x institutional upper limit of normal) or renal disease
             (serum creatinine &gt;2.0 mg/dL)

          -  Participants with significant cardiovascular disease or stroke

          -  Participants with history of seizures

          -  Participants with serious psychiatric illness, including bipolar disorder,
             schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation

          -  Participants who are taking medications such as monoamine oxidase (MAO) inhibitors,
             opioid-containing medications, other naltrexone or bupropion containing medications,
             and Tamoxifen

          -  Current smokers or use of nicotine replacement products in the previous 6 months

          -  Pregnant or breast-feeding women

          -  Any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ji won Lee, MD. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>82-2-2019-3480</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GangnamSeverance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 15, 2018</study_first_submitted>
  <study_first_submitted_qc>July 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gangnam Severance Hospital</investigator_affiliation>
    <investigator_full_name>Ji-Won Lee</investigator_full_name>
    <investigator_title>Associate Professor (Department of Family Medicine, Gangnam Severance Hospital,</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

